clinical trial · NCT07240896
A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
DSciLab Co., Ltd.·early phase1·recruiting·n = 18
Wilsons DiseaseGroup 1: DSL101 Low doseGroup 2: DSL101 Medium doseGroup 3: DSL101 High dose
brief summary
This study adopted an open, single-arm, non-randomized, dose-escalation research design, aiming to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic and immunogenicity characteristics of single and multiple intravenous infusions of DSL101 in patients with Wilson's disease.
started
Dec 31, 2025
primary completion
Apr 1, 2028
completion
Apr 1, 2029
last updated
Jan 20, 2026
detailed description
In this study, low, medium and high dose groups were preset, the low dose group was accelerated titration group, and the medium and high dose groups used the traditional "3+3" method combined with Sentinel method for dose escalation.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol